Color gradient background for Myeloma Connect

Myeloma Connect

What are the qualification criteria for CAR T-cell therapy for patients with multiple myeloma: Which patients to refer and when?

25 January 2022 - 46 Minutes

Faculty

Mohamad Mohty

Hermann Einsele

Yi Lin

EM-78373

Managing adverse events associated with cellular therapies

19 January 2022 - 47 Minutes

Faculty

Michel Delforge

María Victoria Mateos

EM-56870

$What key data have been presented in relapsed/refractory multiple myeloma that you cannot miss from ASH 2021?$

12 January 2022 - 62 Minutes

Faculty

María Victoria Mateos

Hermann Einsele

Philippe Moreau

Niels van de Donk

Rakesh Popat

EM-77812

How does the ASH 2021 data contribute to the roadmap for a cure for newly-diagnosed multiple myeloma?

11 January 2022 - 62 Minutes

Faculty

Michel Delforge

María Victoria Mateos

Mohamad Mohty

Rakesh Popat

Niels van de Donk

Roberto Mina

EM-77809

Is home-based treatment the new way forward?

2 December 2021 - 44 Minutes

Faculty

Mohamad Mohty

Thomas Lund

EM-56872

Practical management of treatment-related adverse events

23 November 2021 - 45 Minutes

Faculty

Michel Delforge

Rakesh Popat

EM-56865

Extramedullary disease: the hard to treat!

10 November 2021 - 48 Minutes

Faculty

Mohamad Mohty

Xavier Leleu

EM-80137

Smoldering MM - to treat or not to treat?

26 October 2021 - 41 Minutes

Faculty

Michel Delforge

María Victoria Mateos

EM-56861

What is the role of tandem transplantation in 2021?

7 October 2021 - 47 Minutes

Faculty

Mohamad Mohty

Niels van de Donk

EM-56859

Addressing the challenge of frail patients with multiple myeloma

23 September 2021 - 41 Minutes

Faculty

Mohamad Mohty

Salomon Manier

EM-56856

1
2
3